Recent Updates
Recently added Catalysts
AKBA Positive Sentiment

Akebia Therapeutics to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026

Wednesday, February 4, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Akebia Therapeutics announced its participation in the Guggenheim Emerging Outlook: Biotech Summit 2026. The executive team will engage in a Fireside Chat on February 12, 2026. The summit will occur in New York City, providing a prominent platform for discussing advancements in biotechnology.
Price reaction · baseline $1.41 (2026-02-03 close) · hit pre-market · clean, no other AKBA news in the window
day 0 close · peak
-2.8%

Market Sentiment Analysis

POSITIVE FACTORS

  • Akebia Therapeutics will present at a significant biotech summit.
  • The event provides a platform for the executive team to share insights.
  • The company is focused on improving lives affected by kidney disease.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+1%
120-day peak, hindsight
Typical move
8%
average across 4 past catalysts
Lead asset
ferric
Phase 3 · Anemia of Chronic Kidney Disease

Full Press Release Details

CAMBRIDGE, Mass., Feb. 04, 2026 (GLOBE NEWSWIRE) --Akebia Therapeutics®, Inc.(Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that members of its executive team will participate in a Fireside Chat at the Guggenheim Emerging Outlook: Biotech Summit 2026 on Thursday, February 12 at 9:30 AM EST.
A webcast of the presentation can be accessed through the “Investors” section of Akebia’s website athttps://ir.akebia.comfollowing the conference.
The Emerging Outlook: Biotech Summit hosted by Guggenheim Securities, LLC, will take place February 11-12, in New York City.

About Akebia Therapeutics

Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease. Akebia was founded in 2007 and is headquartered in Cambridge, Massachusetts. For more information, please visit our website atwww.akebia.com, which does not form a part of this release.

Akebia Therapeutics ContactMercedes Carrascomcarrasco@akebia.com

Frequently Asked Questions

When will Akebia present at the summit?

Akebia Therapeutics will present on February 12, 2026.

Where is the Guggenheim summit taking place?

The summit will be held in New York City.

What is the focus of Akebia Therapeutics?

Akebia aims to improve the lives of those affected by kidney disease.

How can I access the presentation webcast?

The webcast can be accessed through Akebia's website in the 'Investors' section.

ShareAdd on Google
Tags: AKBA Viatris Investor Conferences Healthcare Akebia Therapeutics biotech summit Guggenheim kidney disease executive team
Last updated: Feb 4, 2026

Biotech snapshot

Cash runway
$156M liquidity · $0M/mo burn
Low dilution risk
Lead asset
ferricPhase 3
Anemia of Chronic Kidney Disease →

Catalyst track record

+1%
best trade around AKBA's most recent catalyst

Peak hindsight return over a 120-day window, across 4 tracked FDA/PDUFA catalysts for AKBA.

See every catalyst's timing & PoA →